Clinical Trials Logo

Psychomotor Agitation clinical trials

View clinical trials related to Psychomotor Agitation.

Filter by:

NCT ID: NCT01498120 Completed - Clinical trials for Restless Legs Syndrome

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label, single-arm, optimal dose, long-term follow-up study of monotherapy administration of rotigotine transdermal patch in adolescents with Restless Legs Syndrome (RLS). This study will assess the long-term safety and tolerability of Rotigotine treatment in adolescents with RLS.

NCT ID: NCT01495793 Completed - Clinical trials for Restless Legs Syndrome

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple administrations of the rotigotine transdermal system. The study was conducted in adolescent subjects (13 to <18 years of age) with idiopathic Restless Legs Syndrome (RLS).

NCT ID: NCT01494766 Completed - Clinical trials for Restless Legs Syndrome (RLS)

Efficacy of Tyrosine in Restless Legs Syndrome

Start date: January 2012
Phase: N/A
Study type: Interventional

Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine. It is well known that dopamine deficiency leads to the manifestations of restless legs syndrome (RLS). Studies have shown dopamine agonists and L-dopa to be effective in controlling symptoms. No studies to date have been done to determine the role of tyrosine in RLS. This open-label pilot study aims to determine the efficacy and tolerability of tyrosine in RLS, as current agents have limitations in treating RLS in addition to adding another possible agent to the investigators arsenal of treating RLS that maybe more cost efficient. In this pilot study, the dose of tyrosine will be escalated from 750 mg once daily by mouth (PO) up to 3000 mg once daily PO, as tolerated, in increments of 750 mg every week in patients who meet the inclusion criteria for RLS. Patients' symptoms will be monitored on a weekly basis for six weeks.

NCT ID: NCT01485692 Completed - Clinical trials for Psychomotor Agitation

Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

Start date: February 2009
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy and safety of four options of medications in the management of acute psychomotor agitation,or violence and aggression situations in health services. All of the treatment options are already approved and currently used for this purpose. The options are: haloperidol plus midazolam, haloperidol plus promethazine, olanzapine and ziprasidone. The investigators hypothesized that all treatment options are effective in the treatment of acute agitation, but the combination haloperidol plus promethazine could elicit more adverse affects than the others.

NCT ID: NCT01455012 Completed - Clinical trials for Restless Legs Syndrome

Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome

ENCORE
Start date: September 2011
Phase: Phase 4
Study type: Interventional

Periodic Limb Movements (PLMs) during sleep in patients with Restless Legs Syndrome (RLS) have been shown to be associated with elevations in Blood Pressure (BP). Rotigotine has been shown to effectively reduce the incidence of PLMs in patients with RLS. The current study aims to demonstrate that treatment with Rotigotine could help reduce the number of nocturnal BP elevations associated with PLMs in patients with RLS.

NCT ID: NCT01440114 Completed - Agitation Clinical Trials

The Effect of Intravenous Fentanyl Prior the End of Surgery on Emergence Agitation in Paediatric Patients After General Anesthesia

Start date: March 2010
Phase: N/A
Study type: Interventional

The propose of this study is to determine the effect of intravenous fentanyl prior the end of surgery on the incidence and severity of EA in pediatric patient.

NCT ID: NCT01415323 Completed - Mental Disorders Clinical Trials

Agitation in the Acute Psychiatric Department

Start date: September 2011
Phase:
Study type: Observational

Agitation is associated with a number of acute psychiatric conditions, and frequent in acute psychiatric admissions. It is associated with violence towards others, and strongly associated with in-patient suicides. The main aims of the study are to assess different clinical presentations of agitation at admittance, and to assess the consequences of these different clinical presentations during the first three days of the stay.

NCT ID: NCT01386944 Completed - Clinical trials for Restless Legs Syndrome

Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation

AURORA
Start date: July 2011
Phase:
Study type: Observational

The objective is to assess the effect of Neupro® on the severity of Restless Leg Syndrome (RLS) symptoms and augmentation in patients with augmentation associated with previous oral dopaminergic therapy. In addition, the change in treatment regimen used when switching to Neupro® will be evaluated.

NCT ID: NCT01382901 Completed - Clinical trials for Restless Legs Syndrome (RLS)

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)

NCT ID: NCT01374737 Recruiting - Agitation Clinical Trials

ED50 of Dexmedetomidine to Prevent Emergence Agitation in Children

Start date: June 2011
Phase: Phase 4
Study type: Interventional

There are several recommended doses of dexmedetomidine for prevention of emergence agitation in children. In this study, the investigators examine ED50 in prevention of emergence agitation after tonsillectomy or adenoidectomy in children.